<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Intravascular large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (LBCL) is a rare and aggressive subtype of diffuse LBCL characterized by disseminated intravascular proliferation of neoplastic lymphocytes </plain></SENT>
<SENT sid="1" pm="."><plain>Obstruction of blood flow by <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells in a variety of organs can cause an array of clinical changes, including alteration of the neural and spinal system and the respiratory system, as well as <z:mp ids='MP_0001212'>skin lesions</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>It is usually very difficult to diagnose intravascular LBCL in a patient simply from clinical symptoms or laboratory examinations </plain></SENT>
<SENT sid="3" pm="."><plain>We here document our findings that serum prostatic acid phosphatase levels in both males and a female (2.2-24.0 microg/L) reflect the presence of intravascular LBCL, changing synchronously in response to chemotherapy </plain></SENT>
<SENT sid="4" pm="."><plain>To determine whether prostatic acid phosphatase (<z:mp ids='MP_0010998'>PAP</z:mp>) might be a useful <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> marker for early diagnosis, we reviewed five intravascular LBCLs </plain></SENT>
<SENT sid="5" pm="."><plain>Immunohistochemically, <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells in <z:hpo ids='HP_0000001'>all</z:hpo> cases were positive for anti-<z:mp ids='MP_0010998'>PAP</z:mp> antibody </plain></SENT>
<SENT sid="6" pm="."><plain>The results were further confirmed in one case by Western-blot analysis and in another by the detection of amplified <z:chebi fb="5" ids="33699">messenger RNA</z:chebi> for <z:mp ids='MP_0010998'>PAP</z:mp> in microdissected <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells, respectively </plain></SENT>
<SENT sid="7" pm="."><plain><z:mp ids='MP_0010998'>PAP</z:mp> has not been detected in 17 <z:hpo ids='HP_0002665'>lymphomas</z:hpo> (diffuse LBCL, 8 cases; follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, 3 cases; T-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, 3 cases; Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, 3 cases) by Western blot analyses </plain></SENT>
<SENT sid="8" pm="."><plain>We conclude that serum <z:mp ids='MP_0010998'>PAP</z:mp> is a useful <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> marker for intravascular LBCL and that it deserves further investigation in this context </plain></SENT>
</text></document>